Adaptimmune Therapeutics plc (ADAP) Financials

ADAP Assets vs Liabilities
DateAssetsLiabilities
June 30, 2025 130.6 million 201.6 million
March 31, 2025 158.1 million 195.5 million
Dec. 31, 2024 246.0 million 234.1 million
Sept. 30, 2024 317.4 million 237.4 million

ADAP Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2025 -34.9 million 1.3 million
March 31, 2025 -66.6 million 669000
Dec. 31, 2024 -35.4 million 4.9 million
Sept. 30, 2024 -54.9 million 3.1 million

ADAP Net Income

No data available :(

ADAP Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2025 26.1 million 44.2 million 23.0 million
March 31, 2025 59.6 million 44.1 million 23.3 million
Dec. 31, 2024 151.6 million 69.5 million 24.0 million
Sept. 30, 2024 186.1 million 70.3 million 24.6 million

ADAP Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2025 1.6 billion
March 31, 2025 257.0 million
Dec. 31, 2024 255.9 million
Sept. 30, 2024 255.8 million

ADAP Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2025 75000 23.0 million 17.9 million -
March 31, 2025 1.2 million 28.9 million 23.3 million 360000
Dec. 31, 2024 1.2 million 39.1 million 21.2 million 506000
Sept. 30, 2024 435000 34.3 million 21.3 million -

ADAP Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2025 13.7 million 2.5 million
March 31, 2025 7.3 million 879000
Dec. 31, 2024 3.2 million 2.9 million
Sept. 30, 2024 40.9 million -

ADAP Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ADAP

Price: $0.06

52 week price:
0.02
0.86

Earnings Per Share: -0.66 USD

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United Kingdom

Volume: 237100

Ebitda: 858000

Market Capitalization: 14.6 million

Links: